Completed

Targeted Food Supplements for Appetite Control in Adults with Obesity

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to assess how targeted food supplements can affect the levels of appetite-regulating hormones, such as PYY, GLP-1, and ghrelin, in adults with obesity.

What is being tested

Colonic-delivered DIM + Perilla oil

+ Dietary Supplement: Colonic-delivered Placebo

Dietary Supplement
Who is being recruted

Body Weight+5

+ Nutrition Disorders

+ Nutritional and Metabolic Diseases

From 18 to 60 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: June 2023
See protocol details

Summary

Principal SponsorQueen Mary University of London
Last updated: March 25, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 13, 2023

Actual date on which the first participant was enrolled.

This study is about finding out if a special blend of food supplements, when delivered to the lower gut, can help control appetite and reduce food intake in adults with obesity. The idea is that certain nutrients can trigger the release of hormones that control appetite when they reach specific receptors in the colon. By using a new capsule design, the study aims to deliver these nutrients directly to the lower intestine. The potential outcomes of this study could lead to a non-drug approach for managing appetite in obesity, addressing a significant health challenge. The study follows a randomised, double-blind, placebo-controlled crossover design. Twenty adults with obesity will participate in two study visits, with a break in between. During each visit, they will receive either the active supplement capsules or identical placebo capsules. Blood samples will be taken at regular intervals to measure the levels of appetite-regulating hormones like PYY, GLP-1, and ghrelin. Participants will be served standard breakfast and lunch meals, and their food intake will be recorded. They will also fill out questionnaires to rate their feelings of hunger, fullness, and desire to eat. The active capsules contain diindolylmethane (DIM) and perilla oil, while the placebo capsules contain an inactive substance.

Official TitleThe Effect of Targeted Food Supplements on Gut Hormone Levels
NCT07448519
Principal SponsorQueen Mary University of London
Last updated: March 25, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionOverweight

Criteria

4 inclusion criteria required to participate
Obese but otherwise healthy volunteers aged between 18 and 60 years, of either sex

Body Mass Index (BMI) of 30-40 kg/m^2

Agreement to eat the scheduled meals

Ability to understand the study information sheet and instructions in English, and able to provide informed consent

5 exclusion criteria prevent from participating
Not meeting any of the inclusion criteria above

Major gut surgery involving removal of any part of the gastrointestinal tract

Known major bowel disease

Currently taking medication for diabetes (Type 1 or Type 2)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
Participants in this arm received a colonic delivery capsule containing active ingredients (DIM and perilla oil). Capsules were administered prior to standard breakfast and lunch meals. Food intake, gut hormone release (PYY, GLP-1), and appetite perception (VAS) were monitored. Changes in caloric intake, appetite scores, and gut hormone profiles were expected from the active group.

Group II

Placebo
Participants in this arm received a colonic delivery capsule containing inactive ingredients (placebo: methylcellulose). Capsules were administered prior to standard breakfast and lunch meals. Food intake, gut hormone release (PYY, GLP-1), and appetite perception (VAS) were monitored. No significant changes in caloric intake, appetite scores, or gut hormone profiles were expected from the placebo group.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Wingate Institute of Neurogastroenterology

London, United KingdomOpen Wingate Institute of Neurogastroenterology in Google Maps
CompletedOne Study Center
Targeted Food Supplements for Appetite Control in Adults with Obesity | PatLynk